Cholecystokinin and panic disorder

Acta Neuropsychiatrica

Volumn 16, Issue 2, 2004, Pages 85-93

  Bourin, Michel ^a   Dailly, Eric ^a  

^a UNIVERSITÉ DE NANTES   (France)

Author keywords

Anxiety; Cholecystokinin; Panic disorder

Indexed keywords

CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ RECEPTOR;

ANXIETY DISORDER; NEUROBIOLOGY; NONHUMAN; PANIC; PATHOPHYSIOLOGY; RECEPTOR INTRINSIC ACTIVITY; REVIEW;

EID: 1642503701     PISSN: 09242708     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1601-5215.2004.0076.x     Document Type: Review

References (80)

1. DODD J, KELLY JS. Excitation of CAl pyramidal neurones of the hippocampus by tetra- and octapeptide C-terminal fragments of cholecystokinin. J Physiol 1979;295:61-62.
2. DODD J, KELLY JS. The actions of cholecystokinin and related peptides on pyramidal neurons of the mammalian hippocampus. Brain Res 1981;205:337-350.
3. BODEN P, HILL RG. Effects of cholecystokinin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus. Br J Pharmacol 1988;94:246-252.
4. ISHIBASCHI S, OMURA Y, OKAIJMA T, SHIBATA S. Cholecytokinin, motilin and secretin effects on the central nervous system. Physiol Behav 1979;23:401-403.
5. MacVICAR BA, KERRIN JP, DAVISON JS. Inhibition of synaptic transmission in the dorsal hippocampus by cholecystokinnin (CCK) and its antagonism by a CCK analog (CCK 27-33). Brain Res 1987;406:130-135.
6. LOPES DA SILVA FH, WITTER MP, BOEIJINGA PH, LOHMAN AHM. Anatomical organization and physiology of limbic cortex. Physiol Rev 1990;70:453-511.
7. PINGET M, STRAUSS E, YALOW RS. Localization of cholecystokinin-like reactivity in isolated nerve terminals. Proc Natl Acad Sci USA 1978;75:6321-6326.
8. EMSON PC, LEE OM, REHFELD JF. Cholecystokinin octapeptide: vesicular localization and calcium dependent release from rat brain in vitro. Life Sci 1980;26:2157-2163.
9. GOLTERMANN NR, REHFELD JF, ROIGAARD-PETERSEN H. In vivo biosynthesis of cholecystokinin in rat cerebral cortex. J Biol Chem 1980;255:6181-6185.
10. MIGAUD M, DURIEUX C, ROQUES BP. Evidences of cholecystokinin octapeptide (CCK8) uptake in rat cortex synaptosomal fractions. J Neurochem 1993;61(Suppl.): S83B.
11. REHFELD JF, NIELSEN FC. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In: BRADWEJN J, VASAR E, eds. Cholecystokinin and Anxiety: from Neuron to Behavior. Austin: R.G. Landes, 1995.
12. HILL DR, CAMPBELL NJ, SHAW TM, WOODRUFF GN. Autoradioographic localization and biochemical characterization of peripherical type CCK receptors in rat CNS using highly selective non-peptide CCK agonists. J Neurosci 1987;7:2967-2976.
13. HILL DR, SHAW TM, GRAHAM W, WOODRUFF GN. Autoradiographical detection of cholecystokinin-A receptors in primate brain using 1251-Bolton-Hunter-CCK8 and 3H-MK-329. J Neurosci 1990;10:1070-1081.
14. GERHARDT GA, FRIEDMANN M, BRODIE MS et al. The effect of cholecystokinin (CCK8) on dopamine-containing nerve terminals in the caudale nucleus and nucleus accumbens of the anaesthelized rat in vivo electrochemical studies. Brain Res 1989;499:157-163.
15. VICKROY IW, BIANCHI BR. Pharmacological and mechanistic studies of cholecystokinin-facilitated 3H-dopamine efflux from rat nucleus accumbens. Neuropeptides 1989;13:43-50.
16. WANK SA, HARKINS R, JENSEN RT, SHAPIRA H, DE WEERTH A, SLATTER T. Purification, molecular cloning, and functional expression of the cholecystokinin receptors from rat pancreas. Proc Natl Acad Sci USA 1992;89:3125-3129.
17. ULRICH CD, FERBER I, HOLLCKY E, HADAC E, BUELL G, MILLER LJ. Molecular cloning and functional expression of the human galibladder cholecystokinin A receptor. Biochem Biophys Res Commun 1993;193:204-211.
18. KOPIN AS, LEE Y-M, McBRIDE EW et al. Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 1992;89:3605-3609.
19. LEE Y-M, BEINBORN M, McBRIDE EW, Lu M, KOLAKOWSKi LF, KOPIN AS. The human brain cholecystokinin-B/gastrin receptor. J Biol Chem 1993;268:8164-8169.
20. HUPPI K, SIWARSKI PISENGA JR, WANK S. Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCK-AR and CCK-BR) in human and mouse. Genomics 1995;25:727-729.
21. HONDA I, WADA H, BATTEY JF, WANK SA. Differential gene expression of CCK-A and CCK-B receptors in the rat brain. Mol Cell Neurosci 1993;4:143-154.
22. HAHNE WF, JENSEN RT, LEMP GF, GARDNER JD. Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc Natl Acad Sci USA 1981;78:6304-6308.
23. CHANG RSI, LOTTI VJ. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 1986;83:4923-4926.
24. GULLY D, FREHEL D, MARCY C et al. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCK-A receptors. Eur J Pharmacol 1993;232:13-19.
25. LOTTI VJ, CHANG RS L. A new and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 1989;162:273-280.
26. HUGHES J, BODEN P, COSTALL B et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990;87:6728-6732.
27. HOWBERT JJ, LOBB KL, BROWN RF et al. A novel series of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. In: DOURISH CT, COOPER SJ, IVERSEN SD, IVERSEN LL, eds. Multiple Cholecystokinin Receptors in the CNS. New York: Oxford University Press, 1992.
28. BERTRAND P, BOHME GA, DURIEUX C et al. Pharmacological properties of urido-acetamides, new potent and selective non-peptide CCK-B/gastrin receptor antagonists. Eur J Pharmacol 1994;262:233-245.
29. BOURIN M. Cholecystokinin as a target for neuropsychiatric drugs. Drug News Perspect 1998;11:342-349.
30. BOURIN M, MALINGE M, VASAR E, BRADWEJN J. Two faces of cholecystokinin: anxiety and schizophrenia. Fundam Clin Pharmacol 1996;10:116-120.
31. SHLIK J, VASAR E, BRADWEJN J. Cholecytokinin and psychiatric disorders: role in aetiology and potential of receptor antagonist in therapy. CNS Drugs 1997;8:134-152.
32. DAWSON GR, RUPNIAK NMJ, IVERSEN SD et al. Lack of effect of CCK-B receptor antagonists in ethological and conditioned animal screens for anxiolytic drugs. Psychopharmacology 1995;121:109-117.
33. KÖKS S, MANNISTÔ T, BOURIN M, SHLIK J, VASAR V, VASAR E. Cholecystokinine (CCK) induced anxiety in rats: relevance of preexperimental stress and seasonal variations. J Psychiatr Neurosc 2000;25:33-42.
34. BRADWEJN J, DE MONTIGNY C. Benzodiazepines antagonise cholecystokinin-induced activation of rat hippocampal neurons. Nature 1984;312:363-364.
35. DE MONTIGNY C. Cholecytokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch General Psychiat 1989;46:511-517.
36. BRADWEJN J, KOSZYCI D, METERISSIAN G. Cholecystokinin-tetrapeptide in panic disorder. Can J Psychiat 1990;35:83-85.
37. BRADWEJN J, KOSZYCKI D, SHRIQUI C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch General Psychiatry 1991;48:603-610.
38. ABELSON JL, NESSE RM, VINIK A. Stimulation of corticotrophin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 1991;29:1220-1223.
39. VAN MEGEN HJGM, WESTENBERG HGM, DEN BOER JA, HAIGH JRM, TRAUB M. Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients. Psychopharmacology 1994;114:1021-1033.
40. LYDIARD RB, BALLENGER JC, LARAIA MT, FOSSEY MD, BEINFELD MC. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiat 1992;149:691-693.
41. BRAMBILLA F, BELLODI L, PERNA G, GARBERI A, SACERDOTE P. Lymphocyte cholecytokinin concentrations in panic disorder. Am J Psychiat 1993;150:1111-1113.
42. BRADWEJN J, KOSZYCKI D, COUËTOUX DU TERTRE A, VAN MEGEN H, DEN BOER J, WESTENBERG H, ANNABLE L. The panicogenic effects of cholecystokinin tetrapeptide are antagonised by L-365.260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch General Psychiat 1994;51:486-493.
43. BRADWEJN J. Cholecystokinin and panic disorder. In: BRADWEJN J, VASAR E, eds. Cholecystokinin and Anxiety: from Neuron to Behavior. Austin: RG Landes, 1995.
44. BRADWEJN J, KOSZYCKI D. Imipramine antagonises the panicogenic effects of CCK4 in panic disorder patients. Am J Psychiat 1994;151:261-263.
45. KRAMER MS, CUTLER NR, BALLENGER JC et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 1995;37:462-466.
46. FLINT AJ, KOSZYCKI D, BRADWEJN J, VACCARINO FJ. Neurohormonal responses to cholecystokinin tetrapeptide: a comparison of younger and older healthy subjects. Psychoneuroendocrinology 2000;25:633-647.
47. STRÖHLE A, HOLSBOER F, RUPPRECHT R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology 2000;22:251-256.
48. FLINT AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry 1994;151:640-649.
49. FLINT A, BRADWEJN J, VACCARINo F, GUTKOWSKA J, PALMOUR R, KOSZYCKI D. Aging and panicogenic response to cholecystokinin tetrapeptide: an examination of the cholecystokinin system. Neuropsychopharmacology 2002;27:663-671.
50. Bourin M, Baker GB, Bradwejn J. Neurobiology of panic disorder. J Psychosom Res 1998;44:161-180.
51. MÄNNISTO PT, LANG A, HARRO J, PEURANEN E, BRADWEJN J, VASAR E. Opposite effects mediated by CCKA and CCKB receptors in behavioural and hormonal studies in rats. Naunyn Schmiedebergs Arch Pharmacol 1994;349:478-484.
52. HATTORI E, EBIHARA M, YAMADA K, OHBA H, SHIBUYA H, YOSHIKAWA T. Identification of a compound short tandem repeat stretch in the 5'-upstream region of the cholecystokinin gene, and its association with panic disorder but not with schizophrenia. Mol Psychiatry 2001;6:465-470.
53. HAMILTON SP, SLAGER SL, HELLEBY L et al. No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. Mol Psychiatry 2001;6:59-65.
54. ISE K, AKIYOSHI J, HORINOUCHI Y, TSUTSUMI T, ISOGAWA K, NAGAYAMA H. Association between the CCK-A receptor gene and panic disorder. Am J Med Genet 2003;118B:29-31.
55. HATTORI E, YAMADA K, TOYOTA T et al. Association studies of the CT repeat polymorphism in the 5' upstream region of the cholecystokinin B receptor gene with panic disorder and schizophrenia in Japanese subjects. Am J Med Genet 2001;105:779-782.
56. KENNEDY JL, BRADWEJN J, KOSZYCKI D et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 1999;4:284-285.
57. HARRO J, VASAR E, BRADWEJN J. CCK in animal and human research on anxiety. Trends Pharmacol Sci 1993;14:244-249.
58. BRANCHEREAU P, BOHME GA, CHAMPAGNAT J et al. CholecystokininA and cholecystokininB receptors in neurons of the brainstem solitary complex of the rat: pharmacological identification. J Pharmacol Exp Ther 1992;260:1433-1440.
59. VASAR E, LANG A, HARRO J et al. Subdiaphragmatic vagotomy does not prevent the anti-exploratory effect of caerulein in the elevated plus-maze. Neuropeptides 1994;26:39-45.
60. BRADWEIN J, LEGRAND JM, KOSZYCKI D, BATES J, BOURIN M. Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiat 1998;155:280-282.
61. BRADWEJN J, KOSZVCKI D, COUETOUX DU TERTRE A, BOURIN M, PALMOUR R, ERVIN F. The cholecystokinin hypothesis of panic anxiety disorders: a review. J Psychopharmacol 1992;6:345-351.
62. BEINFELD MC, MEYER DK, ESKAY RL, JENSEN RT, BROWNSTEIN MJ. The distribution of cholecystokinin immunoreactivity in the central nervous system of the rat as determined by radioimmunoassay. Brain Res 1981;212:51-57.
63. TANG F, MAN WS. The regional distribution of thyrotropin releasing hormone, leu-enkephalin, metenkephalin, substance P, somatostatin and cholecystokinin in the rat brain and pituitary. Neuropeptides 1991;19:287-292.
64. SWANSON LW, LIND RW. Neural projections subserving the initiation of a specific motivated behavior in the rat: new projections from the subfornical organ. Brain Res 1986;379:399-403.
65. MEZEY E, REISlNE TD, SKIRBOLL L, BEINFELD M, KISS JZ. Role of cholecystokinin in corticotropin release: coexistence with vasopressin and corticotropin-releasing factor in cells of the rat hypothalamic paraventricular nucleus. Proc Natl Acad Sci USA 1986;83:3510-3512.
66. REISINE T, JENSEN R. Cholecystokinin-8 stimulates adrenocorticotropin release from anterior pituitary cells. J Pharmacol Exp Ther 1986;236:621-626.
67. KAMILARIS TC, JOHNSON EO, CALOGERO AE et al. Cholecystokinin-octapeptide stimulates hypothalamicpituitary-adrenal function in rats: role of corticotropin-releasing hormone. Endocrinology 1992;130:1764-1774.
68. MORLEY JE, MELMED S, BRIGGS J et al. Cholecystokinin octapeptide releases growth hormone from the pituitary in vitro. Life Sci 1979;25:1201-1205.
69. VIJAYAN E, SAMSON WK, McCANN SM. In vivo and in vitro effects of cholecystokinin on gonadotropin, prolactin, growth hormone and thyrotropin release in the rat. Brain Res 1979;172:295-302.
70. SINGH L, FIELD MJ, HUGHES Jet J et al. The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br J Pharmacol 1991;104:239-245.
71. HARRO J, LOFBERG C, REHFELD JF, ORELAND L. Cholecystokinin peptides and receptors in the rat brain during stress. Naunyn Schmiedebergs Arch Pharmacol 1996;354:59-66.
72. PAVLASEVIC S, BEDNAR I, QURESHi GA, SODERSTEN P. Brain cholecystokinin tetrapeptide levels are increased in a rat model of anxiety. Neuroreport 1993;5:225-228.
73. BRANCHEREAU P, CHAMPAGNAT J, ROQUES BP, DENAVIT-SAUBIE M. CCK modulates inhibitory synaptic transmission in the solitary complex through CCKB sites. Neuroreport 1992;3:909-912.
74. PHILIPP E, WILCKENS T, FRIESS E, PLATTE P, PIRKE KM. Cholecystokinin, gastrin and stress hormone responses in marathon runners. Peptides 1992;13:125-128.
75. HARRO J, ORELAND L, VASAR E. cholecystokinin receptors and animal models of anxiety. Clin Neuropharmacol 1992;15(Suppl.)1Pt A:479-480A.
76. FELDMAN M, WALKER P, GOLDSCHMIEDT M, CANNON D. Role of affect and personality in gastric acid secretion and serum gastrin concentration. Comparative studies in normal men and in male duodenal ulcer patients. Gastroenterology 1992;102:175-180.
77. FEKETE M, RENTZSCH A, SCHWARZBERG H, TELEGDY G. Effect of cholecystokinin on self-stimulation behavior in rats. Eur J Pharmacol 1983;91:77-82.
78. HARRO J, KLIIVET RA, LANG A, VASAR E. Rats with or without anxious or non-anxious type of exploratory behavior differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 1990;39:63-71.
79. VASAR E, PEURANEN E, OOPIK T, HARRO J, MANNISTO PT. Ondansetron, an antagonist of 5-HT3 receptors, antagonizes the anti-exploratory effect of caerulein, anagonist of CCK receptors, in the elevated plus-maze. Psychopharmacology (Berl) 1993;110:213-228.
80. COSTALL B, DOMENEY AM, KELLY ME et al. The effect of the 5-HT3 receptor antagonist, RS-42358-197, in animal models of anxiety. Eur J Pharmacol 1993;234:91-99.